Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Dive
preface
classgrid-row grid-gap
Dive
classgrid-col-8

“Real progress is made when industry and regulatory authorities tackle a problem together on the basis of sound scientific principles and hard data that support decision-making.”

  • — Dr. John C. Petricciani

John Petricciani was born in Sacramento, California . He and had a passion for science from an early age. He received his bachelor’s degree BS from Rensselaer Polytechnic Institute, his master of science MS in chemistry from the University of Nevada, and his M.D. from Stanford University. He completed his pediatric internship at Buffalo Children’s Hospital in New York.

In 1968, Dr. Petricciani joined the Public Health Service and was assigned to the Division of Biologics Standards (DBS) at the National Institutes of Health (NIH). He was a medical officer in the Laboratory of Pathology. When the DBS was administratively transferred from the NIH to the Food and Drug Administration (FDA), Dr. Petricciani stayed on in Pathology, rising to the rank of Deputy Director of the Division of Pathology by 1976. He continued to advance quickly at the FDA and became the Assistant Director of Clinical Research, the Special Assistant to the FDA Commissioner, and Director of the Bio-Research Monitoring Program.

Dive
classgrid-col-4

a professional photo of Dr. John Petricciani in a suit with pink tie

Span
classcredit

International Alliance for Biologics Standardization

A photo from the CASSS Hancock Award Ceremony 2017, John C. Petricciani and Wassim Nashabeh, both wearing suits, holding the award

Span
classcaption

Photo from CASSS Hancock Award Ceremony 2017, John C. Petricciani, left, and Wassim Nashabeh, CASSS board member, right

Span
classcredit

CASSS

...

Dr. Petricciani received the 2017 Hancock Award for Outstanding Achievement in CMC Regulatory Science from CASSS, a non-profit science society. Dr. Petricciani received the award , for his long and esteemed career in the biologics regulatory field. His accomplishments highlighted at the award ceremony included his discovery that bacteriophages in childhood vaccines posed no serious health risk for children, his work with the industry and the WHO to establish safety standards for diploid cells used to produce human vaccines, and his landmark published paper that paved the way for the eventual opening of hundreds of clinical research studies of products manufactured in continuous cell lines, and eventually for over 70 currently licensed products.

...